

Special Issue

Emerging Trends and Drug Treatments in Oral Oncology

Message from the Guest Editors

Oral cancer is increasing annually for both genders. Mounting reports demonstrate that more sensitive and novel technologies are developed to detect oral cancer. This improvement provides an early diagnosis of oral cancer and may reduce its death rate. Moreover, several synthetic drugs and natural products were rapidly discovered against different cancers, enhancing their applications for oral cancer treatments. Moreover, combined treatments or natural product extracts (with defined molecular compounds) have the potential for multiple targeting against oral cancer treatments. Drugs showing different types of cell deaths are also welcome, providing numerous choices for oral cancer treatment. Therefore, the novel detection and drug discovery against oral cancer warrant a detailed investigation. This Special Issue aims to host research and review papers on developing novel methodology and technology for oral cancer detection and identifying novel drug treatment or combined treatment for antiproliferation purposes of oral cancer cells. This holds a great promise for improved oral cancer detection and remedies in the future.

Guest Editors

Prof. Dr. Hsueh-Wei Chang

Department of Biomedical Science and Environmental Biology,
Kaohsiung Medical University, Kaohsiung, Taiwan

Prof. Dr. Chien-Chih Chiu

Department of Biotechnology, Kaohsiung Medical University,
Kaohsiung, Taiwan

Deadline for manuscript submissions

closed (15 December 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/128587

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).